| Year |
Citation |
Score |
| 2024 |
Krishna S, Piepho AB, Lake DM, Cumby LR, Lortz KK, Lowe J, Chamberlain JS, Rafael-Fortney JA. Gene therapy delivered micro-dystrophins co-localize with transgenic utrophin in dystrophic skeletal muscle fibers. Neuromuscular Disorders : Nmd. 36: 1-5. PMID 38301403 DOI: 10.1016/j.nmd.2024.01.004 |
0.576 |
|
| 2023 |
Szwec S, Kapłucha Z, Chamberlain JS, Konieczny P. Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review. Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy. 38: 95-119. PMID 37917377 DOI: 10.1007/s40259-023-00632-3 |
0.385 |
|
| 2023 |
Lorena MDSV, Santos EKD, Ferretti R, Nagana Gowda GA, Odom GL, Chamberlain JS, Matsumura CY. Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle. Skeletal Muscle. 13: 16. PMID 37705069 DOI: 10.1186/s13395-023-00325-z |
0.5 |
|
| 2023 |
Hindi SM, Petrany MJ, Greenfeld E, Focke LC, Cramer AAW, Whitt MA, Khairallah RJ, Ward CW, Chamberlain JS, Prasad V, Podbilewicz B, Millay DP. Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery. Cell. 186: 3520. PMID 37541201 DOI: 10.1016/j.cell.2023.06.025 |
0.505 |
|
| 2023 |
Lorena MDSV, Santos EK, Ferretti R, Gowda GAN, Odom GL, Chamberlain JS, Matsumura CY. Biomarkers for Duchenne muscular dystrophy progression: impact of age in the mdx tongue spared muscle. Research Square. PMID 37398370 DOI: 10.21203/rs.3.rs-3038923/v1 |
0.407 |
|
| 2023 |
Benasutti H, Maricelli JW, Seto J, Hall J, Halbert C, Wicki J, Heusgen L, Purvis N, Regnier M, Lin DC, Rodgers BD, Chamberlain JS. Efficacy and muscle safety assessment of fukutin-related protein gene therapy. Molecular Therapy. Methods & Clinical Development. 30: 65-80. PMID 37361354 DOI: 10.1016/j.omtm.2023.05.022 |
0.538 |
|
| 2023 |
Hindi SM, Petrany MJ, Greenfeld E, Focke LC, Cramer AAW, Whitt MA, Khairallah RJ, Ward CW, Chamberlain JS, Podbilewicz B, Prasad V, Millay DP. Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery. Cell. PMID 37075755 DOI: 10.1016/j.cell.2023.03.033 |
0.501 |
|
| 2023 |
Cikes D, Elsayad K, Sezgin E, Koitai E, Torma F, Orthofer M, Yarwood R, Heinz LX, Sedlyarov V, Miranda ND, Taylor A, Grapentine S, Al-Murshedi F, Abot A, Weidinger A, ... ... Chamberlain JS, et al. Author Correction: PCYT2-regulated lipid biosynthesis is critical to muscle health and ageing. Nature Metabolism. PMID 37024756 DOI: 10.1038/s42255-023-00791-1 |
0.313 |
|
| 2023 |
Hindi SM, Petrany MJ, Greenfeld E, Focke LC, Cramer AAW, Whitt MA, Prasad V, Chamberlain JS, Podbilewicz B, Millay DP. Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery. Biorxiv : the Preprint Server For Biology. PMID 36993357 DOI: 10.1101/2023.03.17.533157 |
0.516 |
|
| 2023 |
Cikes D, Elsayad K, Sezgin E, Koitai E, Ferenc T, Orthofer M, Yarwood R, Heinz LX, Sedlyarov V, Miranda ND, Taylor A, Grapentine S, Al-Murshedi F, Abot A, Weidinger A, ... ... Chamberlain JS, et al. PCYT2-regulated lipid biosynthesis is critical to muscle health and ageing. Nature Metabolism. PMID 36941451 DOI: 10.1038/s42255-023-00766-2 |
0.495 |
|
| 2023 |
Piepho AB, Lowe J, Cumby LR, Dorn LE, Lake DM, Rastogi N, Gertzen MD, Sturgill SL, Odom GL, Ziolo MT, Accornero F, Chamberlain JS, Rafael-Fortney JA. Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy model. Molecular Therapy. Methods & Clinical Development. 28: 344-354. PMID 36874243 DOI: 10.1016/j.omtm.2023.02.001 |
0.333 |
|
| 2023 |
Chamberlain J, Robb M, Braun S, Brown K, Danos O, Ganot A, Gonzalez-Alegre P, Hunter N, McDonald C, Morris C, Tobolowsky M, Wagner K, Ziolkowski O, Duan D. Micro-dystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials. Human Gene Therapy. PMID 36694468 DOI: 10.1089/hum.2022.190 |
0.424 |
|
| 2023 |
Birch SM, Lawlor MW, Conlon TJ, Guo LJ, Crudele JM, Hawkins EC, Nghiem PP, Ahn M, Meng H, Beatka MJ, Fickau BA, Prieto JC, Styner MA, Struharik MJ, Shanks C, ... ... Chamberlain JS, et al. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy. Science Translational Medicine. 15: eabo1815. PMID 36599002 DOI: 10.1126/scitranslmed.abo1815 |
0.681 |
|
| 2022 |
Boehler JF, Brown KJ, Beatka M, Gonzalez JP, Donisa Dreghici R, Soustek-Kramer M, McGonigle S, Ganot A, Palmer T, Lowie C, Chamberlain JS, Lawlor MW, Morris CA. Clinical potential of microdystrophin as a surrogate endpoint. Neuromuscular Disorders : Nmd. PMID 36575103 DOI: 10.1016/j.nmd.2022.12.007 |
0.361 |
|
| 2022 |
Chamberlain JS. A Boost for Muscle with Gene Therapy. The New England Journal of Medicine. 386: 1184-1186. PMID 35320650 DOI: 10.1056/NEJMcibr2118576 |
0.514 |
|
| 2022 |
Bengtsson NE, Crudele JM, Klaiman JM, Halbert CL, Hauschka SD, Chamberlain JS. Comparison of dystrophin expression following gene editing and gene replacement in an aged preclinical DMD animal model. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 35143959 DOI: 10.1016/j.ymthe.2022.02.003 |
0.741 |
|
| 2020 |
Banks GB, Chamberlain JS, Odom GL. Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects. Plos Genetics. 16: e1009179. PMID 33175853 DOI: 10.1371/journal.pgen.1009179 |
0.459 |
|
| 2020 |
Bengtsson NE, Tasfaout H, Hauschka SD, Chamberlain JS. Dystrophin gene editing stability is dependent on dystrophin levels in skeletal but not cardiac muscles. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 33160075 DOI: 10.1016/j.ymthe.2020.11.003 |
0.766 |
|
| 2020 |
Hakim CH, Clément N, Wasala LP, Yang HT, Yue Y, Zhang K, Kodippili K, Adamson-Small L, Pan X, Schneider JS, Yang NN, Chamberlain JS, Byrne BJ, Duan D. Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease. Molecular Therapy. Methods & Clinical Development. 18: 664-678. PMID 32775499 DOI: 10.1016/J.Omtm.2020.07.004 |
0.409 |
|
| 2020 |
Li F, Kolb J, Crudele J, Tonino P, Hourani Z, Smith JE, Chamberlain JS, Granzier H. Correction to: Expressing a Z-disk nebulin fragment innebulin-deficient mouse muscle: effects on muscle structure and function. Skeletal Muscle. 10: 9. PMID 32312330 DOI: 10.1186/S13395-020-00223-8 |
0.384 |
|
| 2020 |
Li F, Kolb J, Crudele J, Hourani Z, Smith JE, Chamberlain JS, Granzier H. Expressing a Z-disk nebulin fragment in nebulin-deficient mouse muscle: effects on muscle structure and function. Skeletal Muscle. 10: 2. PMID 31992366 DOI: 10.1186/S13395-019-0219-9 |
0.475 |
|
| 2019 |
Kolwicz SC, Hall JK, Moussavi-Harami F, Chen X, Hauschka SD, Chamberlain JS, Regnier M, Odom GL. Gene Therapy Rescues Cardiac Dysfunction in Duchenne Muscular Dystrophy Mice by Elevating Cardiomyocyte Deoxy-Adenosine Triphosphate. Jacc. Basic to Translational Science. 4: 778-791. PMID 31998848 DOI: 10.1016/J.Jacbts.2019.06.006 |
0.681 |
|
| 2019 |
Davies KE, Chamberlain JS. Surrogate gene therapy for muscular dystrophy. Nature Medicine. PMID 31591598 DOI: 10.1038/s41591-019-0604-2 |
0.316 |
|
| 2019 |
Crudele JM, Chamberlain JS. AAV-based gene therapies for the muscular dystrophies. Human Molecular Genetics. PMID 31238336 DOI: 10.1093/hmg/ddz128 |
0.406 |
|
| 2019 |
Ramos JN, Hollinger K, Bengtsson NE, Allen JM, Hauschka SD, Chamberlain JS. Development of Novel Micro-dystrophins with Enhanced Functionality. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30718090 DOI: 10.1016/J.Ymthe.2019.01.002 |
0.743 |
|
| 2018 |
Kennedy TL, Guiraud S, Edwards B, Squire S, Moir L, Babbs A, Odom G, Golebiowski D, Schneider J, Chamberlain JS, Davies KE. Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/ Mice. Molecular Therapy. Methods & Clinical Development. 11: 92-105. PMID 30417024 DOI: 10.1016/J.Omtm.2018.10.005 |
0.537 |
|
| 2018 |
Park JS, Vohra R, Klussmann T, Bengtsson NE, Chamberlain JS, Lee D. Non-invasive tracking of disease progression in young dystrophic muscles using multi-parametric MRI at 14T. Plos One. 13: e0206323. PMID 30365532 DOI: 10.1371/Journal.Pone.0206323 |
0.419 |
|
| 2018 |
Ho PP, Lahey LJ, Mourkioti F, Kraft PE, Filareto A, Brandt M, Magnusson KEG, Finn EE, Chamberlain JS, Robinson WH, Blau HM, Steinman L. Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy. Proceedings of the National Academy of Sciences of the United States of America. PMID 30181272 DOI: 10.1073/Pnas.1808648115 |
0.429 |
|
| 2018 |
Filareto A, Maguire-Nguyen K, Gan Q, Aldanondo G, Machado L, Chamberlain JS, Rando TA. Monitoring disease activity noninvasively in the model of Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29987034 DOI: 10.1073/pnas.1802425115 |
0.47 |
|
| 2018 |
Nelson DM, Lindsay A, Judge LM, Duan D, Chamberlain JS, Lowe DA, Ervasti JM. Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins. Human Molecular Genetics. PMID 29901725 DOI: 10.1093/hmg/ddy209 |
0.806 |
|
| 2018 |
Nelson DM, Lindsay A, Judge LM, Duan D, Chamberlain JS, Lowe DA, Ervasti JM. Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins. Human Molecular Genetics. PMID 29618008 DOI: 10.1093/Hmg/Ddy113 |
0.83 |
|
| 2018 |
Halbert CL, Allen JM, Chamberlain JS. AAV6 Vector Production and Purification for Muscle Gene Therapy. Methods in Molecular Biology (Clifton, N.J.). 1687: 257-266. PMID 29067669 DOI: 10.1007/978-1-4939-7374-3_18 |
0.43 |
|
| 2018 |
Murray J, Odom G, Olafsson S, Hauschka S, Chamberlain J, Moussavi-Harami F, Regnier M. AAV-Mediated Delivery of Ribonucleotide Reductase and Microdystrophin Rescues Function in Dystrophic Mice Biophysical Journal. 114: 541a. DOI: 10.1016/J.Bpj.2017.11.2956 |
0.613 |
|
| 2017 |
Hakim CH, Wasala NB, Pan X, Kodippili K, Yue Y, Zhang K, Yao G, Haffner B, Duan SX, Ramos J, Schneider JS, Yang NN, Chamberlain JS, Duan D. A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy. Molecular Therapy. Methods & Clinical Development. 6: 216-230. PMID 28932757 DOI: 10.1016/J.Omtm.2017.06.006 |
0.529 |
|
| 2017 |
Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS. Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nature Communications. 8: 16007. PMID 28643790 DOI: 10.1038/Ncomms16007 |
0.724 |
|
| 2017 |
Chamberlain JR, Chamberlain JS. Progress toward Gene Therapy for Duchenne Muscular Dystrophy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 28416280 DOI: 10.1016/J.Ymthe.2017.02.019 |
0.353 |
|
| 2017 |
Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nature Communications. 8: 14454. PMID 28195574 DOI: 10.1038/Ncomms14454 |
0.774 |
|
| 2017 |
Chamberlain J, Ramos J, Hollinger K, Crudele J, Bengtsson N, Hauschka S. Development of microdystrophins for gene therapy of DMD Neuromuscular Disorders. 27: S245. DOI: 10.1016/J.Nmd.2017.06.539 |
0.624 |
|
| 2016 |
Thomson KS, Odom GL, Murry CE, Mahairas GG, Moussavi-Harami F, Teichman SL, Chen X, Hauschka SD, Chamberlain JS, Regnier M. Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy. Jacc. Basic to Translational Science. 1: 666-679. PMID 28553667 DOI: 10.1016/J.Jacbts.2016.07.006 |
0.588 |
|
| 2016 |
Pisconti A, Banks GB, Babaeijandaghi F, Betta ND, Rossi FM, Chamberlain JS, Olwin BB. Loss of niche-satellite cell interactions in syndecan-3 null mice alters muscle progenitor cell homeostasis improving muscle regeneration. Skeletal Muscle. 6: 34. PMID 27906106 DOI: 10.1186/s13395-016-0104-8 |
0.707 |
|
| 2016 |
Pisconti A, Banks GB, Babaeijandaghi F, Betta ND, Rossi FM, Chamberlain JS, Olwin BB. Loss of niche-satellite cell interactions in syndecan-3 null mice alters muscle progenitor cell homeostasis improving muscle regeneration. Skeletal Muscle. 6: 34. PMID 27757223 DOI: 10.1186/S13395-016-0104-8 |
0.707 |
|
| 2016 |
Muir LA, Murry CE, Chamberlain J. Pro-survival factors improve functional engraftment of myogenically converted dermal cells into dystrophic skeletal muscle. Stem Cells and Development. PMID 27503462 DOI: 10.1089/Scd.2016.0136 |
0.758 |
|
| 2016 |
Davey JR, Watt KI, Parker BL, Chaudhuri R, Ryall JG, Cunningham L, Qian H, Sartorelli V, Sandri M, Chamberlain J, James DE, Gregorevic P. Integrated expression analysis of muscle hypertrophy identifies Asb2 as a negative regulator of muscle mass. Jci Insight. 1. PMID 27182554 DOI: 10.1172/Jci.Insight.85477 |
0.579 |
|
| 2016 |
Bengtsson NE, Hall JK, Odom GL, Allen J, Chamberlain JR, Chamberlain JS. 501. In Vivo Gene Editing for Duchenne Muscular Dystrophy Molecular Therapy. 24: S199. DOI: 10.1016/S1525-0016(16)33310-X |
0.507 |
|
| 2016 |
Hakim C, Pan X, Kodippili K, Blessa T, Yang HT, Yao G, Leach S, Emter C, Yue Y, Zhang K, Duan SX, Wasala N, Jenkins G, Legg CR, Schneider JS, ... Chamberlain JS, et al. 499. Intravenous Delivery of a Novel Micro-Dystrophin Vector Prevented Muscle Deterioration in Young Adult Canine Duchenne Muscular Dystrophy Dogs Molecular Therapy. 24: S198-S199. DOI: 10.1016/S1525-0016(16)33308-1 |
0.541 |
|
| 2016 |
Banks GB, Nguyen Q, Hauschka SD, Chamberlain JS, Odom GL. 380. Therapeutic Capacity of AAV-Delivered Muscle-Specific-Expressed Micro-Utrophin (ΔR4-R21/ΔCT) in mdX4cv Skeletal Muscles Molecular Therapy. 24: S151-S152. DOI: 10.1016/S1525-0016(16)33189-6 |
0.724 |
|
| 2015 |
Ramos J, Chamberlain JS. Gene Therapy for Duchenne muscular dystrophy. Expert Opinion On Orphan Drugs. 3: 1255-1266. PMID 26594599 DOI: 10.1517/21678707.2015.1088780 |
0.458 |
|
| 2015 |
Bengtsson NE, Seto JT, Hall JK, Chamberlain JS, Odom GL. Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Human Molecular Genetics. PMID 26450518 DOI: 10.1093/Hmg/Ddv420 |
0.309 |
|
| 2015 |
Hollinger K, Chamberlain JS. Viral vector-mediated gene therapies. Current Opinion in Neurology. 28: 522-7. PMID 26263476 DOI: 10.1097/WCO.0000000000000241 |
0.316 |
|
| 2015 |
Bisset DR, Stepniak-Konieczna EA, Zavaljevski M, Wei J, Carter GT, Weiss MD, Chamberlain JR. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Human Molecular Genetics. PMID 26082468 DOI: 10.1093/Hmg/Ddv219 |
0.38 |
|
| 2015 |
Park J, Wicki J, Knoblaugh SE, Chamberlain JS, Lee D. Multi-parametric MRI at 14T for muscular dystrophy mice treated with AAV vector-mediated gene therapy. Plos One. 10: e0124914. PMID 25856443 DOI: 10.1371/journal.pone.0124914 |
0.38 |
|
| 2015 |
Hall JK, Mozaffarian LL, Chamberlain JS. 617. Histologic Assessment of Geriatric Esophagus Revels Therapeutic Targets in Wild-Type and Dystrophic Mouse Models Molecular Therapy. 23: S245. DOI: 10.1016/S1525-0016(16)34226-5 |
0.413 |
|
| 2015 |
Bengtsson NE, Hall JK, Lieber AM, Chamberlain JS. 613. Characterization of IPSC-Derived Myogenic Progenitors Isolated from Mouse Models of Duchenne Muscular Dystrophy Molecular Therapy. 23: S243-S244. DOI: 10.1016/S1525-0016(16)34222-8 |
0.501 |
|
| 2015 |
Halbert C, Goddard M, Lee D, Mack D, Butts T, Grange R, Johnson M, Storb R, Miller D, Chamberlain J, Tapscott S, Childers M, Wang Z. 398. Sustained Expression of a Canine Micro-Dystrophin Lead To Improvement of Limb Muscle Function in Dystrophic Dogs Following Large Scale AAV-Mediated Treatment Molecular Therapy. 23: S158. DOI: 10.1016/S1525-0016(16)34007-2 |
0.611 |
|
| 2015 |
Moussavi-Harami F, Razumova MV, Cheng Y, Odom G, Teichman S, Tardiff J, Hauschka SD, Chamberlain JS, Murry CM, Regnier M. 11. Gene Therapy Mediated Increase in dATP Improves Cardiac Performance in Models of Systolic Heart Failure Molecular Therapy. 23: S5. DOI: 10.1016/S1525-0016(16)33615-2 |
0.604 |
|
| 2015 |
Chamberlain J, Seto J, Ramos J, Hauschka S, Odom G. Gene delivery to large animal models using AAV vectors Neuromuscular Disorders. 25: S290. DOI: 10.1016/J.Nmd.2015.06.372 |
0.628 |
|
| 2014 |
Arnett AL, Konieczny P, Ramos JN, Hall J, Odom G, Yablonka-Reuveni Z, Chamberlain JR, Chamberlain JS. Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Molecular Therapy. Methods & Clinical Development. 1. PMID 25580445 DOI: 10.1038/Mtm.2014.38 |
0.8 |
|
| 2014 |
Muir LA, Nguyen QG, Hauschka SD, Chamberlain JS. Engraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal muscle. Molecular Therapy. Methods & Clinical Development. 1: 14025. PMID 25558461 DOI: 10.1038/Mtm.2014.25 |
0.828 |
|
| 2014 |
Wei J, Chamberlain JR. Systemic RNAi delivery to the muscles of ROSA26 mice reduces lacZ expression. Plos One. 9: e102053. PMID 25127128 DOI: 10.1371/Journal.Pone.0102053 |
0.542 |
|
| 2014 |
Swiderski K, Shaffer SA, Gallis B, Odom GL, Arnett AL, Scott Edgar J, Baum DM, Chee A, Naim T, Gregorevic P, Murphy KT, Moody J, Goodlett DR, Lynch GS, Chamberlain JS. Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting. Human Molecular Genetics. 23: 6697-711. PMID 25082828 DOI: 10.1093/Hmg/Ddu388 |
0.712 |
|
| 2014 |
Banks GB, Combs AC, Odom GL, Bloch RJ, Chamberlain JS. Muscle structure influences utrophin expression in mdx mice. Plos Genetics. 10: e1004431. PMID 24922526 DOI: 10.1371/Journal.Pgen.1004431 |
0.466 |
|
| 2014 |
Faber RM, Hall JK, Chamberlain JS, Banks GB. Myofiber branching rather than myofiber hyperplasia contributes to muscle hypertrophy in mdx mice. Skeletal Muscle. 4: 10. PMID 24910770 DOI: 10.1186/2044-5040-4-10 |
0.5 |
|
| 2014 |
Seto JT, Bengtsson NE, Chamberlain JS. Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy. Current Pediatrics Reports. 2: 102-112. PMID 24883236 DOI: 10.1007/S40124-014-0044-X |
0.478 |
|
| 2014 |
Pearson T, Kabayo T, Ng R, Chamberlain J, McArdle A, Jackson MJ. Skeletal muscle contractions induce acute changes in cytosolic superoxide, but slower responses in mitochondrial superoxide and cellular hydrogen peroxide. Plos One. 9: e96378. PMID 24875639 DOI: 10.1371/Journal.Pone.0096378 |
0.46 |
|
| 2014 |
Taghli-Lamallem O, Jagla K, Chamberlain JS, Bodmer R. Mechanical and non-mechanical functions of Dystrophin can prevent cardiac abnormalities in Drosophila. Experimental Gerontology. 49: 26-34. PMID 24231130 DOI: 10.1016/j.exger.2013.10.015 |
0.398 |
|
| 2014 |
Chamberlain J, Ramos J, Banks G, Hauschka S. G.P.95 Neuromuscular Disorders. 24: 823. DOI: 10.1016/J.Nmd.2014.06.109 |
0.73 |
|
| 2014 |
Gay E, Nowakowski SG, Kolwicz SC, Odom GL, Flint GV, Stuppard R, Gu H, Chamberlain JS, Raftery D, Tian R, Marcinek DJ, Regnier M. AAV6-Mediated Overexpression of Ribonucleotide Reductase (R1R2) Enhances 2-Deoxy-ATP Concentration in Vivo and Improves Cardiac Function Biophysical Journal. 106: 345a. DOI: 10.1016/J.Bpj.2013.11.1970 |
0.372 |
|
| 2013 |
Ieronimakis N, Pantoja M, Hays AL, Dosey TL, Qi J, Fischer KA, Hoofnagle AN, Sadilek M, Chamberlain JS, Ruohola-Baker H, Reyes M. Increased sphingosine-1-phosphate improves muscle regeneration in acutely injured mdx mice. Skeletal Muscle. 3: 20. PMID 23915702 DOI: 10.1186/2044-5040-3-20 |
0.507 |
|
| 2013 |
Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated therapies for muscular dystrophy. Muscle & Nerve. 47: 649-63. PMID 23553671 DOI: 10.1002/mus.23738 |
0.368 |
|
| 2013 |
Filareto A, Parker S, Darabi R, Borges L, Iacovino M, Schaaf T, Mayerhofer T, Chamberlain JS, Ervasti JM, McIvor RS, Kyba M, Perlingeiro RC. An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nature Communications. 4: 1549. PMID 23462992 DOI: 10.1038/Ncomms2550 |
0.38 |
|
| 2013 |
Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, et al. Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 266-8. PMID 23369965 DOI: 10.1038/Mt.2013.4 |
0.359 |
|
| 2013 |
Arnett AL, Beutler LR, Quintana A, Allen J, Finn E, Palmiter RD, Chamberlain JS. Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction. Gene Therapy. 20: 497-503. PMID 22855092 DOI: 10.1038/Gt.2012.60 |
0.754 |
|
| 2012 |
Winbanks CE, Weeks KL, Thomson RE, Sepulveda PV, Beyer C, Qian H, Chen JL, Allen JM, Lancaster GI, Febbraio MA, Harrison CA, McMullen JR, Chamberlain JS, Gregorevic P. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. The Journal of Cell Biology. 197: 997-1008. PMID 22711699 DOI: 10.1083/jcb.201109091 |
0.422 |
|
| 2012 |
Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE, Allen JM, Miller AD, Chamberlain JS, Tapscott SJ. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1501-7. PMID 22692496 DOI: 10.1038/mt.2012.111 |
0.542 |
|
| 2012 |
Seto JT, Ramos JN, Muir L, Chamberlain JS, Odom GL. Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors. Current Gene Therapy. 12: 139-51. PMID 22533379 DOI: 10.2174/156652312800840603 |
0.686 |
|
| 2012 |
Ng R, Banks GB, Hall JK, Muir LA, Ramos JN, Wicki J, Odom GL, Konieczny P, Seto J, Chamberlain JR, Chamberlain JS. Animal models of muscular dystrophy. Progress in Molecular Biology and Translational Science. 105: 83-111. PMID 22137430 DOI: 10.1016/B978-0-12-394596-9.00004-4 |
0.67 |
|
| 2012 |
Korte FS, Odom GL, Dai J, Kolwicz SC, Robinson-Hamm JN, Tian R, Hauschka SD, Chamberlain JS, Weiss RS, Murry CE, Regnier M. Broad Transgenic, and Cardiac-Specific Viral Mediated, Over-Expression of Ribonucleotide Reductase Increases In Vivo Cardiac Contractility Biophysical Journal. 102: 615a. DOI: 10.1016/J.Bpj.2011.11.3351 |
0.573 |
|
| 2012 |
Arnett ALH, Ramos JN, Chamberlain JS. Gene therapy of skeletal muscle disorders using viral vectors Muscle. 2: 1045-1051. DOI: 10.1016/B978-0-12-381510-1.00076-4 |
0.507 |
|
| 2011 |
Arnett AL, Garikipati D, Wang Z, Tapscott S, Chamberlain JS. Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector. Frontiers in Microbiology. 2: 220. PMID 22065964 DOI: 10.3389/Fmicb.2011.00220 |
0.625 |
|
| 2011 |
Wang Z, Tapscott SJ, Chamberlain JS, Storb R. Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials. Frontiers in Microbiology. 2: 201. PMID 21980317 DOI: 10.3389/fmicb.2011.00201 |
0.392 |
|
| 2011 |
Judge LM, Arnett AL, Banks GB, Chamberlain JS. Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice. Human Molecular Genetics. 20: 4978-90. PMID 21949353 DOI: 10.1093/Hmg/Ddr433 |
0.862 |
|
| 2011 |
Suga T, Kimura E, Morioka Y, Ikawa M, Li S, Uchino K, Uchida Y, Yamashita S, Maeda Y, Chamberlain JS, Uchino M. Muscle fiber type-predominant promoter activity in lentiviral-mediated transgenic mouse. Plos One. 6: e16908. PMID 21445245 DOI: 10.1371/journal.pone.0016908 |
0.529 |
|
| 2011 |
Goyenvalle A, Seto JT, Davies KE, Chamberlain J. Therapeutic approaches to muscular dystrophy. Human Molecular Genetics. 20: R69-78. PMID 21436158 DOI: 10.1093/Hmg/Ddr105 |
0.528 |
|
| 2011 |
Odom GL, Gregorevic P, Allen JM, Chamberlain JS. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 36-45. PMID 20859263 DOI: 10.1038/mt.2010.205 |
0.364 |
|
| 2010 |
Chamberlain JS. Duchenne muscular dystrophy models show their age. Cell. 143: 1040-2. PMID 21183068 DOI: 10.1016/j.cell.2010.12.005 |
0.331 |
|
| 2010 |
Hall JK, Banks GB, Chamberlain JS, Olwin BB. Prevention of muscle aging by myofiber-associated satellite cell transplantation. Science Translational Medicine. 2: 57ra83. PMID 21068442 DOI: 10.1126/Scitranslmed.3001081 |
0.709 |
|
| 2010 |
Carter GT, Han JJ, Chamberlain JR, Chamberlain JS. On fixing broken muscle...fall seven times, stand up eight--Japanese proverb. Muscle & Nerve. 41: 737-9. PMID 20513100 DOI: 10.1002/Mus.21704 |
0.454 |
|
| 2010 |
Banks GB, Judge LM, Allen JM, Chamberlain JS. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. Plos Genetics. 6: e1000958. PMID 20502633 DOI: 10.1371/Journal.Pgen.1000958 |
0.774 |
|
| 2010 |
Odom GL, Banks GB, Schultz BR, Gregorevic P, Chamberlain JS. Preclinical studies for gene therapy of Duchenne muscular dystrophy. Journal of Child Neurology. 25: 1149-57. PMID 20498332 DOI: 10.1177/0883073810371006 |
0.787 |
|
| 2010 |
Li D, Bareja A, Judge L, Yue Y, Lai Y, Fairclough R, Davies KE, Chamberlain JS, Duan D. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. Journal of Cell Science. 123: 2008-13. PMID 20483958 DOI: 10.1242/Jcs.064808 |
0.823 |
|
| 2010 |
Friedrich O, Both M, Weber C, Schürmann S, Teichmann MD, von Wegner F, Fink RH, Vogel M, Chamberlain JS, Garbe C. Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophysical Journal. 98: 606-16. PMID 20159157 DOI: 10.1016/J.Bpj.2009.11.005 |
0.407 |
|
| 2010 |
Chamberlain JR, Chamberlain JS. Muscling in: Gene therapies for muscular dystrophy target RNA. Nature Medicine. 16: 170-1. PMID 20134472 DOI: 10.1038/Nm0210-170 |
0.498 |
|
| 2010 |
Wang Z, Storb R, Lee D, Kushmerick MJ, Chu B, Berger C, Arnett A, Allen J, Chamberlain JS, Riddell SR, Tapscott SJ. Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 617-24. PMID 20040912 DOI: 10.1038/Mt.2009.294 |
0.684 |
|
| 2010 |
Kimura E, Li S, Gregorevic P, Fall BM, Chamberlain JS. Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 206-13. PMID 19888194 DOI: 10.1038/mt.2009.253 |
0.564 |
|
| 2010 |
Kimura E, Uchino K, Suga T, Koide T, Uchida Y, Maeda Y, Yamashita S, Chamberlain J, Uchino M. P3.10 Lentiviral vector mediated delivery of full-length dystrophin for gene therapy of muscular dystrophy Neuromuscular Disorders. 20: 643-644. DOI: 10.1016/J.Nmd.2010.07.152 |
0.428 |
|
| 2010 |
Garikipati D, Chamberlain JS. Systemic gene delivery for muscle gene therapy Muscle Gene Therapy. 163-179. DOI: 10.1007/978-1-4419-1207-7_10 |
0.464 |
|
| 2009 |
Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, Chamberlain JS. Erratum to "Efficient Transduction of Skeletal Muscle Using Vectors Based on Adeno-associated Virus Serotype 6". Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1482. PMID 28160909 DOI: 10.1038/Mt.2009.135 |
0.817 |
|
| 2009 |
Townsend D, Yasuda S, Chamberlain J, Metzger JM. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy. Trends in Cardiovascular Medicine. 19: 50-55. PMID 19577712 DOI: 10.1016/J.Tcm.2009.04.006 |
0.562 |
|
| 2009 |
Muir LA, Chamberlain JS. Emerging strategies for cell and gene therapy of the muscular dystrophies. Expert Reviews in Molecular Medicine. 11: e18. PMID 19555515 DOI: 10.1017/S1462399409001100 |
0.736 |
|
| 2009 |
Gregorevic P, Schultz BR, Allen JM, Halldorson JB, Blankinship MJ, Meznarich NA, Kuhr CS, Doremus C, Finn E, Liggitt D, Chamberlain JS. Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1427-33. PMID 19471246 DOI: 10.1038/Mt.2009.116 |
0.836 |
|
| 2009 |
Arnett AL, Chamberlain JR, Chamberlain JS. Therapy for neuromuscular disorders. Current Opinion in Genetics & Development. 19: 290-7. PMID 19411172 DOI: 10.1016/J.Gde.2009.03.005 |
0.747 |
|
| 2009 |
Wang Z, Chamberlain JS, Tapscott SJ, Storb R. Gene therapy in large animal models of muscular dystrophy. Ilar Journal / National Research Council, Institute of Laboratory Animal Resources. 50: 187-98. PMID 19293461 |
0.375 |
|
| 2009 |
Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL, Duan D. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. The Journal of Clinical Investigation. 119: 624-35. PMID 19229108 DOI: 10.1172/Jci36612 |
0.818 |
|
| 2009 |
Banks GB, Chamberlain JS, Froehner SC. Truncated dystrophins can influence neuromuscular synapse structure. Molecular and Cellular Neurosciences. 40: 433-41. PMID 19171194 DOI: 10.1016/j.mcn.2008.12.011 |
0.447 |
|
| 2009 |
Boyle K, Chamberlain J. 19-P029 Identifying genes regulating the quiescent state in muscle satellite cells Mechanisms of Development. 126: S299-S300. DOI: 10.1016/j.mod.2009.06.817 |
0.418 |
|
| 2009 |
Teichmann MD, von Wegner F, Fink RH, Chamberlain JS, Launikonis BS, Martinac B, Friedrich O. Ca2+ Spark Activity in Intact Dystrophin-Deficient mdx Muscle during Osmotic Challenge is Triggered by Mechanosensitive Pathways Biophysical Journal. 96: 22a-23a. DOI: 10.1016/J.Bpj.2008.12.1018 |
0.354 |
|
| 2008 |
Banks GB, Chamberlain JS. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Current Topics in Developmental Biology. 84: 431-53. PMID 19186250 DOI: 10.1016/S0070-2153(08)00609-1 |
0.394 |
|
| 2008 |
Percival JM, Anderson KN, Gregorevic P, Chamberlain JS, Froehner SC. Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. Plos One. 3: e3387. PMID 18852886 DOI: 10.1371/journal.pone.0003387 |
0.552 |
|
| 2008 |
Banks GB, Combs AC, Chamberlain JR, Chamberlain JS. Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Human Molecular Genetics. 17: 3975-86. PMID 18799475 DOI: 10.1093/Hmg/Ddn301 |
0.335 |
|
| 2008 |
Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1539-45. PMID 18665159 DOI: 10.1038/mt.2008.149 |
0.563 |
|
| 2008 |
Friedrich O, von Wegner F, Chamberlain JS, Fink RH, Rohrbach P. L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle. Plos One. 3: e1762. PMID 18516256 DOI: 10.1371/journal.pone.0001762 |
0.321 |
|
| 2008 |
Kimura E, Han JJ, Li S, Fall B, Ra J, Haraguchi M, Tapscott SJ, Chamberlain JS. Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Human Molecular Genetics. 17: 2507-17. PMID 18511457 DOI: 10.1093/hmg/ddn151 |
0.522 |
|
| 2008 |
Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1189-99. PMID 18500252 DOI: 10.1038/Mt.2008.103 |
0.741 |
|
| 2008 |
Stone D, Liu Y, Li ZY, Strauss R, Finn EE, Allen JM, Chamberlain JS, Lieber A. Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery. Journal of Virology. 82: 7711-5. PMID 18480442 DOI: 10.1128/JVI.00542-08 |
0.358 |
|
| 2008 |
Friedrich O, Weber C, Wegner FV, Chamberlain JS, Fink RHA. Unloaded speed of shortening in voltage-clamped intact skeletal muscle fibers from wt, mdx, and transgenic minidystrophin mice using a novel high-speed acquisition system Biophysical Journal. 94: 4751-4765. PMID 18424498 DOI: 10.1529/biophysj.107.126557 |
0.403 |
|
| 2008 |
Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 832-5. PMID 18414480 DOI: 10.1038/Mt.2008.52 |
0.504 |
|
| 2008 |
Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 657-64. PMID 18334986 DOI: 10.1038/Mt.2008.28 |
0.825 |
|
| 2008 |
Faulkner JA, Ng R, Davis CS, Li S, Chamberlain JS. Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clinical and Experimental Pharmacology & Physiology. 35: 725-9. PMID 18215182 DOI: 10.1111/J.1440-1681.2007.04865.X |
0.535 |
|
| 2008 |
Gregorevic P, Meznarich NA, Blankinship MJ, Crawford RW, Chamberlain JS. Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. Muscle & Nerve. 37: 104-6. PMID 17691104 DOI: 10.1002/Mus.20877 |
0.8 |
|
| 2007 |
Percival JM, Gregorevic P, Odom GL, Banks GB, Chamberlain JS, Froehner SC. rAAV6-microdystrophin rescues aberrant Golgi complex organization in mdx skeletal muscles. Traffic (Copenhagen, Denmark). 8: 1424-39. PMID 17714427 DOI: 10.1111/j.1600-0854.2007.00622.x |
0.506 |
|
| 2007 |
Xiong F, Xiao S, Yu M, Li W, Zheng H, Shang Y, Peng F, Zhao C, Zhou W, Chen H, Fang L, Chamberlain JS, Zhang C. Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transport. Bmc Neuroscience. 8: 50. PMID 17617925 DOI: 10.1186/1471-2202-8-50 |
0.372 |
|
| 2007 |
Banks GB, Gregorevic P, Allen JM, Finn EE, Chamberlain JS. Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Human Molecular Genetics. 16: 2105-13. PMID 17588958 DOI: 10.1093/hmg/ddm158 |
0.493 |
|
| 2007 |
Xiong F, Xiao S, Peng F, Zheng H, Yu M, Ruan Y, Li W, Shang Y, Zhao C, Zhou W, Chen H, Chamberlain JS, Fang L, Zhang C. Herpes simplex virus VP22 enhances adenovirus-mediated microdystrophin gene transfer to skeletal muscles in dystrophin-deficient (mdx) mice. Human Gene Therapy. 18: 490-501. PMID 17550336 DOI: 10.1089/hum.2006.155 |
0.5 |
|
| 2007 |
Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, Metzger JM. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1086-92. PMID 17440445 DOI: 10.1038/Sj.Mt.6300144 |
0.776 |
|
| 2007 |
Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS, Tapscott SJ, Storb R. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1160-6. PMID 17426713 DOI: 10.1038/Sj.Mt.6300161 |
0.803 |
|
| 2007 |
Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 2195-204. PMID 17360850 DOI: 10.1096/Fj.06-7353Com |
0.32 |
|
| 2007 |
Dellavalle A, Sampaolesi M, Tonlorenzi R, Tagliafico E, Sacchetti B, Perani L, Innocenzi A, Galvez BG, Messina G, Morosetti R, Li S, Belicchi M, Peretti G, Chamberlain JS, Wright WE, et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature Cell Biology. 9: 255-67. PMID 17293855 DOI: 10.1038/ncb1542 |
0.456 |
|
| 2007 |
Chamberlain JS. ACE inhibitor bulks up muscle. Nature Medicine. 13: 125-6. PMID 17290265 DOI: 10.1038/nm0207-125 |
0.391 |
|
| 2007 |
Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, Finn EE, Nguyen QG, Blankinship MJ, Meuse L, Chamberlain JS, Hauschka SD. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 320-9. PMID 17235310 DOI: 10.1038/Sj.Mt.6300027 |
0.846 |
|
| 2007 |
Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ, Chamberlain JS, Kuhr CS. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Human Gene Therapy. 18: 18-26. PMID 17176210 DOI: 10.1089/hum.2006.093 |
0.444 |
|
| 2007 |
Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochimica Et Biophysica Acta. 1772: 243-62. PMID 17064882 DOI: 10.1016/j.bbadis.2006.09.007 |
0.525 |
|
| 2007 |
Gregorevic P, Chamberlain JS. Therapeutic Gene Transfer to Skeletal Muscle Concepts in Genetic Medicine. 123-128. DOI: 10.1002/9780470184585.ch9 |
0.526 |
|
| 2006 |
Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nature Medicine. 12: 787-9. PMID 16819550 DOI: 10.1038/Nm1439 |
0.842 |
|
| 2006 |
Bachrach E, Perez AL, Choi YH, Illigens BM, Jun SJ, del Nido P, McGowan FX, Li S, Flint A, Chamberlain J, Kunkel LM. Muscle engraftment of myogenic progenitor cells following intraarterial transplantation. Muscle & Nerve. 34: 44-52. PMID 16634061 DOI: 10.1002/Mus.20560 |
0.584 |
|
| 2006 |
Li S, Kimura E, Ng R, Fall BM, Meuse L, Reyes M, Faulkner JA, Chamberlain JS. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Human Molecular Genetics. 15: 1610-22. PMID 16595609 DOI: 10.1093/Hmg/Ddl082 |
0.488 |
|
| 2006 |
Judge LM, Haraguchiln M, Chamberlain JS. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. Journal of Cell Science. 119: 1537-46. PMID 16569668 DOI: 10.1242/Jcs.02857 |
0.808 |
|
| 2006 |
Blankinship MJ, Gregorevic P, Chamberlain JS. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 13: 241-9. PMID 16361117 DOI: 10.1016/J.Ymthe.2005.11.001 |
0.813 |
|
| 2006 |
Han JJ, Carter GT, Ra JJ, Abresch RT, Chamberlain JS, Robinson LR. Electromyographic studies in mdx and wild-type C57 mice. Muscle & Nerve. 33: 208-14. PMID 16281275 DOI: 10.1002/mus.20455 |
0.482 |
|
| 2006 |
Reyes M, Krishnamurty A, Brain S, Judge J, Chamberlain JS. In Vivo Systemic Transduction of the Vasculature Using rAAV6. Blood. 108: 3254-3254. DOI: 10.1182/Blood.V108.11.3254.3254 |
0.5 |
|
| 2006 |
Salva MZ, Himeda CL, Tai P, Nishiuchi E, Finn EE, Allen JM, Gregorevic P, Blankinship MJ, Meuse LA, Chamberlain JS, Hauschka SD. 561. Novel Tissue-Specific Regulatory Cassettes Direct High-Level Transgene Expression in Skeletal and Cardiac Muscle Molecular Therapy. 13: S216. DOI: 10.1016/J.Ymthe.2006.08.634 |
0.841 |
|
| 2006 |
Gregorevic P, Blankinship MJ, Minami E, Allen JM, Murry CE, Chamberlain JS. 35. Systemic Administration of rAAV6-Microdystrophin Preserves Muscle Function and Extends Lifespan in the Dystrophin-/Utrophin- Mouse Model of Severe Muscular Dystrophy Molecular Therapy. 13: S15. DOI: 10.1016/J.Ymthe.2006.08.048 |
0.856 |
|
| 2005 |
Judge LM, Chamberlain JS. Gene therapy for Duchenne muscular dystrophy: AAV leads the way. Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology / Edited by the Gaetano Conte Academy For the Study of Striated Muscle Diseases. 24: 184-93. PMID 16629052 |
0.758 |
|
| 2005 |
Lai Y, Yue Y, Liu M, Ghosh A, Engelhardt JF, Chamberlain JS, Duan D. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nature Biotechnology. 23: 1435-9. PMID 16244658 DOI: 10.1038/Nbt1153 |
0.434 |
|
| 2005 |
Gregorevic P, Chamberlain JS. Functional enhancement of skeletal muscle by gene transfer. Physical Medicine and Rehabilitation Clinics of North America. 16: 875-87, vii-viii. PMID 16214049 DOI: 10.1016/j.pmr.2005.08.011 |
0.515 |
|
| 2005 |
Abmayr S, Gregorevic P, Allen JM, Chamberlain JS. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 441-50. PMID 16099410 DOI: 10.1016/j.ymthe.2005.04.001 |
0.579 |
|
| 2005 |
Weisbart RH, Hansen JE, Nishimura RN, Chan G, Wakelin R, Chang SS, Baresi L, Chamberlain JS. An intracellular delivery vehicle for protein transduction of micro-dystrophin. Journal of Drug Targeting. 13: 81-7. PMID 15823959 DOI: 10.1080/10611860400029002 |
0.362 |
|
| 2005 |
Li S, Kimura E, Fall BM, Reyes M, Angello JC, Welikson R, Hauschka SD, Chamberlain JS. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Therapy. 12: 1099-108. PMID 15759015 DOI: 10.1038/Sj.Gt.3302505 |
0.761 |
|
| 2005 |
Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS, Duan D. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 245-56. PMID 15668136 DOI: 10.1016/J.Ymthe.2004.09.013 |
0.781 |
|
| 2005 |
Reyes M, Chamberlain JS. Perivascular CD45−:Sca-1+:CD34− Cells Are Derived from Bone Marrow Cells and Participate in Dystrophic Skeletal Muscle Regeneration. Blood. 106: 394-394. DOI: 10.1182/Blood.V106.11.394.394 |
0.505 |
|
| 2004 |
Gregorevic P, Blankinship MJ, Chamberlain JS. Viral vectors for gene transfer to striated muscle. Current Opinion in Molecular Therapeutics. 6: 491-8. PMID 15537050 |
0.849 |
|
| 2004 |
Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, Miller DA, Chamberlain JS. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 671-8. PMID 15451451 DOI: 10.1016/J.Ymthe.2004.07.016 |
0.865 |
|
| 2004 |
Ge Y, Molloy MP, Chamberlain JS, Andrews PC. Differential expression of the skeletal muscle proteome in mdx mice at different ages. Electrophoresis. 25: 2576-85. PMID 15300778 DOI: 10.1002/Elps.200406013 |
0.429 |
|
| 2004 |
Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW, Chamberlain JS. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nature Medicine. 10: 828-34. PMID 15273747 DOI: 10.1038/Nm1085 |
0.852 |
|
| 2004 |
Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, Flint A, Chamberlain J, Kunkel LM. Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proceedings of the National Academy of Sciences of the United States of America. 101: 3581-6. PMID 14993597 DOI: 10.1073/Pnas.0400373101 |
0.52 |
|
| 2004 |
Reyes M, Li S, Kimura E, Meuse L, Chamberlain J. 379. Myogenic Differentiation of Multipotent Adult Progenitor Cells Derived from Bone Marrow and Muscle Tissue Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.314 |
0.577 |
|
| 2003 |
Abmayr S, Crawford RW, Chamberlain JS. Characterization of ARC, apoptosis repressor interacting with CARD, in normal and dystrophin-deficient skeletal muscle. Human Molecular Genetics. 13: 213-21. PMID 14645204 DOI: 10.1093/HMG/DDH018 |
0.511 |
|
| 2003 |
Ge Y, Molloy MP, Chamberlain JS, Andrews PC. Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity. Proteomics. 3: 1895-903. PMID 14625851 DOI: 10.1002/Pmic.200300561 |
0.446 |
|
| 2003 |
Yue Y, Li Z, Harper SQ, Davisson RL, Chamberlain JS, Duan D. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation. 108: 1626-32. PMID 12952841 DOI: 10.1161/01.Cir.0000089371.11664.27 |
0.741 |
|
| 2003 |
Gregorevic P, Chamberlain JS. Gene therapy for muscular dystrophy - a review of promising progress. Expert Opinion On Biological Therapy. 3: 803-14. PMID 12880380 DOI: 10.1517/14712598.3.5.803 |
0.473 |
|
| 2003 |
Scott JM, Chamberlain JS. Gutted adenoviral vectors for gene transfer to muscle. Methods in Molecular Biology (Clifton, N.J.). 219: 19-28. PMID 12596996 |
0.506 |
|
| 2003 |
Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yamamoto H, Li J, Chamberlain JS, Xiao X, Takeda S. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Therapy. 9: 1576-88. PMID 12424610 DOI: 10.1038/Sj.Gt.3301829 |
0.581 |
|
| 2002 |
Chamberlain JS. Gene therapy of muscular dystrophy. Human Molecular Genetics. 11: 2355-62. PMID 12351570 |
0.412 |
|
| 2002 |
DelloRusso C, Scott JM, Hartigan-O'Connor D, Salvatori G, Barjot C, Robinson AS, Crawford RW, Brooks SV, Chamberlain JS. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proceedings of the National Academy of Sciences of the United States of America. 99: 12979-84. PMID 12271128 DOI: 10.1073/Pnas.202300099 |
0.873 |
|
| 2002 |
Gussoni E, Bennett RR, Muskiewicz KR, Meyerrose T, Nolta JA, Gilgoff I, Stein J, Chan YM, Lidov HG, Bönnemann CG, Von Moers A, Morris GE, Den Dunnen JT, Chamberlain JS, Kunkel LM, et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. The Journal of Clinical Investigation. 110: 807-14. PMID 12235112 DOI: 10.1172/Jci16098 |
0.399 |
|
| 2002 |
Barjot C, Hartigan-O'Connor D, Salvatori G, Scott JM, Chamberlain JS. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses. The Journal of Gene Medicine. 4: 480-9. PMID 12221641 DOI: 10.1002/Jgm.305 |
0.597 |
|
| 2002 |
Scott JM, Li S, Harper SQ, Welikson R, Bourque D, DelloRusso C, Hauschka SD, Chamberlain JS. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscular Disorders : Nmd. 12: S23-9. PMID 12206791 DOI: 10.1016/S0960-8966(02)00078-0 |
0.855 |
|
| 2002 |
Harper SQ, Crawford RW, DelloRusso C, Chamberlain JS. Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable. Human Molecular Genetics. 11: 1807-15. PMID 12140183 DOI: 10.1093/Hmg/11.16.1807 |
0.805 |
|
| 2002 |
Crosbie RH, Dovico SA, Flanagan JD, Chamberlain JS, Ownby CL, Campbell KP. Characterization of aquaporin-4 in muscle and muscular dystrophy. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 16: 943-9. PMID 12087055 DOI: 10.1096/Fj.01-0327Com |
0.523 |
|
| 2002 |
Spencer MJ, Guyon JR, Sorimachi H, Potts A, Richard I, Herasse M, Chamberlain J, Dalkilic I, Kunkel LM, Beckmann JS. Stable expression of calpain 3 from a muscle transgene in vivo: immature muscle in transgenic mice suggests a role for calpain 3 in muscle maturation. Proceedings of the National Academy of Sciences of the United States of America. 99: 8874-9. PMID 12084932 DOI: 10.1073/Pnas.132269299 |
0.599 |
|
| 2002 |
Warner LE, DelloRusso C, Crawford RW, Rybakova IN, Patel JR, Ervasti JM, Chamberlain JS. Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Human Molecular Genetics. 11: 1095-105. PMID 11978768 DOI: 10.1093/Hmg/11.9.1095 |
0.828 |
|
| 2002 |
Hartigan-O'Connor D, Barjot C, Salvatori G, Chamberlain JS. Generation and growth of gutted adenoviral vectors. Methods in Enzymology. 346: 224-46. PMID 11883070 DOI: 10.1016/S0076-6879(02)46058-2 |
0.588 |
|
| 2002 |
Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV, Chamberlain JS. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nature Medicine. 8: 253-61. PMID 11875496 DOI: 10.1038/Nm0302-253 |
0.872 |
|
| 2002 |
Hartigan-O'Connor D, Barjot C, Crawford R, Chamberlain JS. Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection. Human Gene Therapy. 13: 519-31. PMID 11874630 DOI: 10.1089/10430340252809810 |
0.617 |
|
| 2002 |
Crawford GE, Lu QL, Partridge TA, Chamberlain JS. Suppression of revertant fibers in mdx mice by expression of a functional dystrophin. Human Molecular Genetics. 10: 2745-50. PMID 11734539 DOI: 10.1093/Hmg/10.24.2745 |
0.592 |
|
| 2001 |
Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. Journal of Muscle Research and Cell Motility. 22: 467-75. PMID 11964072 DOI: 10.1023/A:1014587918367 |
0.848 |
|
| 2001 |
Hartigan-O'Connor D, Kirk CJ, Crawford R, Mulé JJ, Chamberlain JS. Immune evasion by muscle-specific gene expression in dystrophic muscle. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 525-33. PMID 11735336 DOI: 10.1006/Mthe.2001.0496 |
0.773 |
|
| 2001 |
Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. The Journal of Physiology. 535: 591-600. PMID 11533147 DOI: 10.1111/J.1469-7793.2001.00591.X |
0.428 |
|
| 2001 |
Kolodziejczyk SM, Walsh GS, Balazsi K, Seale P, Sandoz J, Hierlihy AM, Rudnicki MA, Chamberlain JS, Miller FD, Megeney LA. Activation of JNK1 contributes to dystrophic muscle pathogenesis Current Biology. 11: 1278-1282. PMID 11525743 DOI: 10.1016/S0960-9822(01)00397-9 |
0.487 |
|
| 2000 |
Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy Human Molecular Genetics. 9: 2507-2515. PMID 11030755 DOI: 10.1093/Hmg/9.17.2507 |
0.557 |
|
| 2000 |
Lynch GS, Rafael JA, Chamberlain JS, Faulkner JA. Contraction-induced injury to single permeabilized muscle fibers from mdx, transgenic mdx, and control mice. American Journal of Physiology. Cell Physiology. 279: C1290-4. PMID 11003610 DOI: 10.1152/Ajpcell.2000.279.4.C1290 |
0.332 |
|
| 2000 |
Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner SC, Chamberlain JS. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. The Journal of Cell Biology. 150: 1399-410. PMID 10995444 DOI: 10.1083/Jcb.150.6.1399 |
0.609 |
|
| 2000 |
Hauser MA, Robinson A, Hartigan-O'Connor D, Williams-Gregory DA, Buskin JN, Apone S, Kirk CJ, Hardy S, Hauschka SD, Chamberlain JS. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 2: 16-25. PMID 10899824 DOI: 10.1006/Mthe.2000.0089 |
0.844 |
|
| 2000 |
Rafael JA, Townsend ER, Squire SE, Potter AC, Chamberlain JS, Davies KE. Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. Human Molecular Genetics. 9: 1357-67. PMID 10814717 DOI: 10.1093/HMG/9.9.1357 |
0.495 |
|
| 2000 |
Disatnik MH, Chamberlain JS, Rando TA. Dystrophin mutations predict cellular susceptibility to oxidative stress. Muscle & Nerve. 23: 784-92. PMID 10797403 DOI: 10.1002/(SICI)1097-4598(200005)23:5<784::AID-MUS17>3.0.CO;2-Y |
0.433 |
|
| 2000 |
Hartigan-O'Connor D, Chamberlain JS. Developments in gene therapy for muscular dystrophy. Microscopy Research and Technique. 48: 223-38. PMID 10679969 DOI: 10.1002/(Sici)1097-0029(20000201/15)48:3/4<223::Aid-Jemt10>3.0.Co;2-L |
0.777 |
|
| 1999 |
Hartigan-O'Connor D, Amalfitano A, Chamberlain JS. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase Journal of Virology. 73: 7835-7841. PMID 10438876 DOI: 10.1128/Jvi.73.9.7835-7841.1999 |
0.612 |
|
| 1999 |
Lumeng C, Phelps S, Crawford GE, Walden PD, Barald K, Chamberlain JS. Interactions between beta 2-syntrophin and a family of microtubule-associated serine/threonine kinases. Nature Neuroscience. 2: 611-7. PMID 10404183 DOI: 10.1038/10165 |
0.651 |
|
| 1999 |
Lumeng CN, Hauser M, Brown V, Chamberlain JS. Expression of the 71 kDa dystrophin isoform (Dp71) evaluated by gene targeting. Brain Research. 830: 174-8. PMID 10350571 DOI: 10.1016/S0006-8993(99)01201-9 |
0.649 |
|
| 1999 |
Lumeng CN, Phelps SF, Rafael JA, Cox GA, Hutchinson TL, Begy CR, Adkins E, Wiltshire R, Chamberlain JS. Characterization of dystrophin and utrophin diversity in the mouse. Human Molecular Genetics. 8: 593-9. PMID 10072426 DOI: 10.1093/HMG/8.4.593 |
0.627 |
|
| 1998 |
Crosbie RH, Straub V, Yun HY, Lee JC, Rafael JA, Chamberlain JS, Dawson VL, Dawson TM, Campbell KP. mdx muscle pathology is independent of nNOS perturbation. Human Molecular Genetics. 7: 823-9. PMID 9536086 DOI: 10.1093/Hmg/7.5.823 |
0.47 |
|
| 1998 |
Kinoshita I, Vilquin JT, Asselin I, Chamberlain J, Tremblay JP. Transplantation of myoblasts from a transgenic mouse overexpressing dystrophin prduced only a relatively small increase of dystrophin-positive membrane. Muscle & Nerve. 21: 91-103. PMID 9427228 DOI: 10.1002/(Sici)1097-4598(199801)21:1<91::Aid-Mus12>3.0.Co;2-3 |
0.436 |
|
| 1997 |
Straub V, Rafael JA, Chamberlain JS, Campbell KP. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. The Journal of Cell Biology. 139: 375-85. PMID 9334342 DOI: 10.1083/Jcb.139.2.375 |
0.472 |
|
| 1997 |
Hauser MA, Amalfitano A, Kumar-Singh R, Hauschka SD, Chamberlain JS. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromuscular Disorders : Nmd. 7: 277-83. PMID 9267841 DOI: 10.1016/S0960-8966(97)00052-7 |
0.77 |
|
| 1997 |
Lynch GS, Rafael JA, Hinkle RT, Cole NM, Chamberlain JS, Faulkner JA. Contractile properties of diaphragm muscle segments from old mdx and old transgenic mdx mice. The American Journal of Physiology. 272: C2063-8. PMID 9227435 DOI: 10.1152/Ajpcell.1997.272.6.C2063 |
0.443 |
|
| 1997 |
Amalfitano A, Chamberlain JS. Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: Implications for gene therapy Gene Therapy. 4: 258-263. PMID 9135740 DOI: 10.1038/Sj.Gt.3300378 |
0.358 |
|
| 1997 |
Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Human Molecular Genetics. 5: 913-21. PMID 8817325 DOI: 10.1093/HMG/5.7.913 |
0.493 |
|
| 1996 |
Chao DS, Gorospe JR, Brenman JE, Rafael JA, Peters MF, Froehner SC, Hoffman EP, Chamberlain JS, Bredt DS. Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. The Journal of Experimental Medicine. 184: 609-18. PMID 8760814 DOI: 10.1084/Jem.184.2.609 |
0.395 |
|
| 1996 |
Rafael JA, Cox GA, Corrado K, Jung D, Campbell KP, Chamberlain JS. Forced expression of dystrophin deletion constructs reveals structure-function correlations. The Journal of Cell Biology. 134: 93-102. PMID 8698825 DOI: 10.1083/Jcb.134.1.93 |
0.342 |
|
| 1995 |
Bueno MR, Moreira ES, Vainzof M, Chamberlain J, Marie SK, Pereira L, Akiyama J, Roberds SL, Campbell KP, Zatz M. A common missense mutation in the adhalin gene in three unrelated Brazilian families with a relatively mild form of autosomal recessive limb-girdle muscular dystrophy. Human Molecular Genetics. 4: 1163-7. PMID 8528203 DOI: 10.1093/Hmg/4.7.1163 |
0.335 |
|
| 1995 |
Yang B, Jung D, Rafael JA, Chamberlain JS, Campbell KP. Identification of alpha-syntrophin binding to syntrophin triplet, dystrophin, and utrophin. The Journal of Biological Chemistry. 270: 4975-8. PMID 7890602 DOI: 10.1074/Jbc.270.10.4975 |
0.322 |
|
| 1995 |
Phelps SF, Hauser MA, Cole NM, Rafael JA, Hinkle RT, Faulkner JA, Chamberlain JS. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Human Molecular Genetics. 4: 1251-8. PMID 7581361 DOI: 10.1093/Hmg/4.8.1251 |
0.45 |
|
| 1994 |
Cox GA, Sunada Y, Campbell KP, Chamberlain JS. Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. Nature Genetics. 8: 333-9. PMID 7894482 DOI: 10.1038/Ng1294-333 |
0.463 |
|
| 1994 |
Rafael JA, Sunada Y, Cole NM, Campbell KP, Faulkner JA, Chamberlain JS. Prevention of dystrophic pathology in mdx mice by a truncated dystrophin isoform. Human Molecular Genetics. 3: 1725-33. PMID 7849695 DOI: 10.1093/Hmg/3.10.1725 |
0.533 |
|
| 1993 |
Cox GA, Cole NM, Matsumura K, Phelps SF, Hauschka SD, Campbell KP, Faulkner JA, Chamberlain JS. Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature. 364: 725-9. PMID 8355788 DOI: 10.1038/364725A0 |
0.745 |
|
| 1993 |
Cox GA, Phelps SF, Chapman VM, Chamberlain JS. New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nature Genetics. 4: 87-93. PMID 8099842 DOI: 10.1038/ng0593-87 |
0.423 |
|
| 1991 |
Lee CC, Pearlman JA, Chamberlain JS, Caskey CT. Expression of recombinant dystrophin and its localization to the cell membrane. Nature. 349: 334-6. PMID 1824797 DOI: 10.1038/349334a0 |
0.587 |
|
| 1991 |
Hoffman EP, Garcia CA, Chamberlain JS, Angelini C, Lupski JR, Fenwick R. Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of Duchenne muscular dystrophy. Annals of Neurology. 30: 605-10. PMID 1789686 DOI: 10.1002/Ana.410300414 |
0.419 |
|
| 1991 |
Blonden LAJ, Grootscholten PM, den Dunnen JT, Bakker E, Abbs S, Bobrow M, Boehm C, van Broeckhoven C, Baumbach L, Chamberlain J, Caskey CT, Denton M, Felicetti L, Galluzi G, Fischbeck KH, et al. 242 Breakpoints in the 200-kb deletion-prone P20 region of the DMD gene are widely spread Genomics. 10: 631-639. PMID 1679746 DOI: 10.1016/0888-7543(91)90445-K |
0.489 |
|
| 1990 |
Ballabio A, Ranier JE, Chamberlain JS, Zollo M, Caskey CT. Screening for steroid sulfatase (STS) gene deletions by multiplex DNA amplification. Human Genetics. 84: 571-3. PMID 2338343 DOI: 10.1007/Bf00210812 |
0.437 |
|
| 1989 |
Towbin JA, Wu DR, Chamberlain J, Larsen PD, Seltzer WK, McCabe ER. Characterization of patients with glycerol kinase deficiency utilizing cDNA probes for the Duchenne muscular dystrophy locus. Human Genetics. 83: 122-6. PMID 2550352 DOI: 10.1007/Bf00286703 |
0.307 |
|
| 1989 |
McCabe ER, Towbin J, Chamberlain J, Baumbach L, Witkowski J, van Ommen GJ, Koenig M, Kunkel LM, Seltzer WK. Complementary DNA probes for the Duchenne muscular dystrophy locus demonstrate a previously undetectable deletion in a patient with dystrophic myopathy, glycerol kinase deficiency, and congenital adrenal hypoplasia. The Journal of Clinical Investigation. 83: 95-9. PMID 2536049 DOI: 10.1172/Jci113890 |
0.343 |
|
| 1988 |
Chamberlain JS, Pearlman JA, Muzny DM, Gibbs RA, Ranier JE, Caskey CT, Reeves AA. Expression of the murine Duchenne muscular dystrophy gene in muscle and brain. Science (New York, N.Y.). 239: 1416-8. PMID 3347839 DOI: 10.1126/Science.3347839 |
0.655 |
|
| 1986 |
Jaynes JB, Chamberlain JS, Buskin JN, Johnson JE, Hauschka SD. Transcriptional regulation of the muscle creatine kinase gene and regulated expression in transfected mouse myoblasts. Molecular and Cellular Biology. 6: 2855-64. PMID 3785216 DOI: 10.1128/Mcb.6.8.2855 |
0.655 |
|
| 1985 |
Chamberlain JS, Jaynes JB, Hauschka SD. Regulation of creatine kinase induction in differentiating mouse myoblasts. Molecular and Cellular Biology. 5: 484-92. PMID 3990682 DOI: 10.1128/Mcb.5.3.484 |
0.578 |
|
| 1983 |
Hauschka S, Lim B, Clegg C, Chamberlain J, Linkhart T. Cell replication, mitogen receptors, and regulation of the commitment to terminal differentiation in mouse myoblasts Cell Biology International Reports. 7: 553-554. DOI: 10.1016/0309-1651(83)90174-1 |
0.564 |
|
| Show low-probability matches. |